跳至主要内容
临床试验/NCT02457988
NCT02457988终止早期 1 期

COORS: The Cirrhosis Outpatient Optimization, Readmission & Safety Study

University of California, Los Angeles2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2015年4月1日最近更新:
适应症
干预措施

试验速览

阶段
早期 1 期
状态
终止
入组人数
120
试验地点
2
主要终点
Number of 30-day readmissions between intervention and control group

研究概览

简要总结

A prospective series comparing care incorporating home monitoring and liver care coordination to conventional care for patients with cirrhosis.

详细描述

Telemonitoring has been suggested to have potential benefits in patients with cirrhosis. However, to date, no prospective studies exist to support this idea. Hence, the investigators study would like to explore the use of home telemonitoring devices with vital sign capturing capabilities in recently-discharged patients with cirrhosis to decrease 30-day readmissions, mortality and costs.

This is prospective, randomized controlled trial comparing two strategies of post-discharged care in patients with cirrhosis-related hospitalizations.

First treatment arm will incorporate the Vivify home monitoring device into post hospital care.Home monitoring kits include a tablet with wireless internet and vital sign monitoring capabilities (temperature, blood pressure, heart rate, weight and pulse oximetry if needed) and the device has the ability to trigger an alert to the "liver care coordinator."

Second treatment arm will continue the standard of care therapy that all post- hospitalized patients receive upon discharge, i.e. return to clinic appointments, education regarding any signs or worsening symptoms to watch for, as well as contact numbers to connect with their doctor or nurse.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ascites requiring paracentesis during the hospitalization
  • Hepatic encephalopathy defined as altered mental status that improves after treatment with lactulose
  • Variceal hemorrhage, defined as clinically significant gastrointestinal bleed (tachycardia, hypotension, requirement for blood transfusion, or >2g drop in hemoglobin) and varices seen on endoscopy
  • Spontaneous bacterial peritonitis defined as >250 polymorphonuclear cells per high-power field and/or monomicrobial culture in the ascetic fluid
  • Renal failure in the presence of ascites, defined as a rise in the serum creatinine by 0.5mg/dl (to >1.5mg/dl), with ascites documented on physical exam or ultrasound, or admitted on diuretics for the treatment of ascites
  • Hyponatremia, defined by serum sodium <130 on admission labs
  • Hepatocellular carcinoma as seen on arterial phase MRI or liver biopsy, if tumor is treated and fits within Milan criteria

排除标准

  • Admissions for scheduled or elective procedures
  • Patients with a comorbid conditions with a life expectancy of less than 12 months or ones that may confound a patient's clinical course
  • Hepatocellular carcinoma
  • Hepatorenal syndrome
  • Hepatopulmonary syndrome
  • Metastatic cancer
  • Chronic kidney disease (pre-dialysis, dialysis)
  • Congestive heart failure
  • Diagnosed dementia
  • Pregnancy or planned pregnancy during the study
  • Those managed by palliative care
  • Patients with liver transplants prior to or during the index hospitalization
  • Patients unable to understand study procedures/instructions/use of the home monitoring device
  • Patients unable to stand for <1 minute
  • Patients living in nursing homes or similar institutions

研究组 & 干预措施

Vivify Kit

Experimental

Patients with cirrhosis will undergo home monitoring for 30 days post-discharge through the use of the Vivify kit which contains a wireless tablet with daily medication/diet/symptom questionnaires and vital sign monitoring.

干预措施: Vivify Kit (Device)

Standard of Care

No Intervention

Patients with cirrhosis will undergo standard of care, which includes a post-discharge lab check and follow-up clinic appointment. Otherwise, no day-to-day monitoring of these patients will occur.

结局指标

主要结局

Number of 30-day readmissions between intervention and control group

时间窗: 30 days

Compare hospital readmission rates between the intervention group (device) and control group

次要结局

  • Blood pressure control(30 days)
  • Number of emergency room visits between the two study groups for ED visits within 30 days post discharge. (composite measure)(30 days)
  • Weight compliance(30 days)
  • Medication compliance(30 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验